December 2017December 2017
New Contraindications
Coadministration of Genvoya (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide) is contraindicated with drugs that are highly dependent on CYP3A for clearance and for which elevated plasma concentrations are associated with serious and/or life threatening events, and with drugs that are potent inducers of CYP3A due to the potential for loss of virologic response and possible resistance to Genvoya.
Motilium (domperidone) is contraindicated with known existing prolongation of cardiac conduction intervals, particularly QTc, patients with significant electrolyte disturbances underlying cardiac diseases such as congestive heart failure.
Resprim, Resprim Forte (sulfamethoxazole/trimethoprim) should not be given to babies during the first six weeks of life because of the risk of producing kernicterus.
Coadministration of Xatral SR (alfuzosin hydrochloride) with potent CYP3A4 inhibitors is contraindicated.
Coadministration of Zerit (stavudine) with didanosine is contraindicated due to the potential for serious and/or life-threatening events notably lactic acidosis, liver function abnormalities, pancreatitis, and peripheral neuropathy.
Copyright © MIMS Australia Pty Ltd. All rights reserved.
MIMS Australia
Level 2, 1 Chandos Street
St Leonards NSW 2065
Phone: 1800 800 629
info@mims.com.au
www.mims.com.au